Compare · PRVA vs REUN
PRVA vs REUN
Side-by-side comparison of Privia Health Group Inc. (PRVA) and Reunion Neuroscience Inc. (REUN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRVA and REUN operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- PRVA carries a market cap of $3.21B.
- PRVA has hit the wire 9 times in the past 4 weeks while REUN has been quiet.
- PRVA has more recent analyst coverage (25 ratings vs 0 for REUN).
- Company
- Privia Health Group Inc.
- Reunion Neuroscience Inc.
- Price
- $25.50+2.16%
- $1.13+1.80%
- Market cap
- $3.21B
- -
- 1M return
- +4.04%
- -
- 1Y return
- +29.28%
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Privia Health Group Inc.
Privia Health Group, Inc. operates as a physician practice management and population health technology company in the United States. The company comprises regional medical groups, accountable care organizations, and specialty verticals. It offers technology and population health tools to enhance independent providers' workflows; management service organization that enables providers to reduce administrative work focus on their patients; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; physician-led accountable care organization, which engages patients, reduces inappropriate utilization, and enhances coordination and patient quality metrics to drive value-based care and transform the healthcare delivery system; and network for purchasers and payers. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. operates as a subsidiary of Brighton Health Group Holdings, LLC.
Latest PRVA
- EVP & Chief Financial Officer Mountcastle David sold $588,679 worth of shares (21,275 units at $27.67) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 164,853 units (SEC Form 4)
- EVP & Chief Financial Officer Mountcastle David sold $16,542 worth of shares (600 units at $27.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.32% to 186,128 units (SEC Form 4)
- Privia Health Group Inc. filed SEC Form 8-K: Leadership Update
- Director Morris Matthew Shawn exercised 112,759 shares at a strike of $2.00 and sold $3,076,868 worth of shares (112,759 units at $27.29) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 68,188 units (SEC Form 4)
- EVP & Chief Financial Officer Mountcastle David sold $680,185 worth of shares (24,734 units at $27.50) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 186,728 units (SEC Form 4)
- Privia Health to Report Second Quarter 2026 Results on Thursday, August 6
- Director Morris Matthew Shawn exercised 135,498 shares at a strike of $2.00 and sold $3,566,335 worth of shares (135,498 units at $26.32) as part of a pre-agreed trading plan (SEC Form 4)
- Director Morris Matthew Shawn exercised 151,322 shares at a strike of $2.00 and sold $3,832,986 worth of shares (151,322 units at $25.33) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & Chief Financial Officer Mountcastle David exercised 17,196 shares at a strike of $2.00 and sold $432,995 worth of shares (17,196 units at $25.18) as part of a pre-agreed trading plan (SEC Form 4)
- Privia Health Enters New Jersey
Latest REUN
- SEC Form 15-12G filed by Reunion Neuroscience Inc.
- Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
- Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
- SEC Form 6-K filed by Reunion Neuroscience Inc.
- SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)
- SEC Form F-10POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form 25-NSE filed by Reunion Neuroscience Inc.
- Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement